In a report that appears in the Journal of Clinical Oncology, researchers have shown that a subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of targeted treatments that zero in on the breast cancer cells themselves. That could enable some women to avoid the "sledgehammer" of typical chemotherapy drugs that kill normal and tumor cells alike and avoid triggering resistance in tumor cells. Read more here.
Study mentioned: Rimawi MF, et al. Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006. J Clin Oncol. 2013 Apr 8. [Epub ahead of print] PMID: 23569315
No comments:
Post a Comment